Evidence shows that clinician training in effective strategies for tobacco dependence increases the delivery of these interventions. The second issue of Counseling Points - Breaking Barriers and Implementing Change will be an educational resource to help nurses accomplish this training. The importance of partnering with patients to maximize intervention outcomes will be explained. Recommended brief and intensive interventions for tobacco dependence will be described, with evidence supporting their usefulness in clinical practice. Similarly, available pharmacologic interventions will be reviewed in terms of their pharmacokinetic profiles, dosing, indications, contraindications, and adverse events profiles. Recognizing the risks factors for relapse and strategies for relapse prevention also will be addressed.
Daryl Sharp, PhD, PMHCNS-BC, NPP
Director, Doctor of Nursing Practice Program
Associate Professor of Clinical Nursing and in the Center for Community Health University of Rochester Medical Center, Rochester, New York
Jacques (Jack) Amole, DNP, RN, CNSPMH-BC
Medical College of GA
School of Nursing
Martha P. Fankhauser, MS Pharm, FASHP, BCPP
Department of Pharmacy Practice and Sciences
College of Pharmacy
The University of Arizona Health Science Center
Steven A. Schroeder, MD
Department of Medicine and Smoking Cessation Leadership Center
University of California, San Francisco
San Francisco, California
APNA and Faculty Disclosure Statements:
Accredited status of an activity does not imply APNA or ANCC Commission on Accreditation endorsement of commercial products. Jacques (Jack) Amole, Martha Fankhauser, Steven Schroeder, and Daryl Sharp have no conflicts to disclose.
This educational activity is designed to meet the needs of psychiatric nurses with an interest in providing quality care to patients with mental illness who smoke.
Upon completion of this educational activity, the participant should be able to:
1. Discuss recommended strategies for delivering brief and intensive tobacco dependence interventions and strategies to prevent relapse in persons with mental illness
2. Review nicotine replacement therapies that are effective in persons with mental illness, and their pharmacologic profiles, dosing regimens, indications, contraindications, and adverse events profiles
3. Review non-nicotine products that are effective in persons with mental illness, and their pharmacologic profiles, dosing regimens, indications, contraindications, and adverse events profiles
Continuing Education Credit
1.0 contact hours may be earned for successful completion of this activity. * In order to receive contact hours, you must: Read the entire publication, complete an evaluation, and earn a passing score on the post test before the expiration date. You will have 5 tries to earn a score of 80% or better on the post test. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. We cannot award credit unless all steps are completed.
The contact hours for this continuing education activity will expire September 30, 2012.
The American Psychiatric Nurses Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. The American Psychiatric Nurses Association, Delaware Media Group, and Pfizer, Inc. do not recommend the use of any agent outside of the FDA-approved labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the American Psychiatric Nurses Association, Delaware Media Group, or Pfizer, Inc.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any medications, diagnostic procedures, or treatments discussed in this publication should not be used by clinicians or other healthcare professionals without first evaluating their patients' conditions, considering possible contraindications or risks, reviewing any applicable manufacturer's product information, and comparing any therapeutic approach with the recommendations of other authorities.